Drug Overview

R-gossypol acetic acid (also known as AT-101) is a specialized “Smart Drug” derived from the seeds of the cotton plant. While it is natural in origin, it has been chemically refined for use as a high-precision cancer treatment. It belongs to the class of Targeted Therapies because it focuses on the internal survival switches that prevent cancer cells from dying.

In the world of oncology, R-gossypol acetic acid is recognized as a potent BH3-mimetic. This means it mimics a natural protein that tells a cell its time is up. For patients, this offers a unique way to treat aggressive tumors that have become resistant to standard chemotherapy. It is currently being utilized in advanced clinical research to treat a variety of solid tumors and blood-related cancers across the US and European markets.

Generic Name: R-gossypol acetic acid (AT-101)
US Brand Names: None (Currently an investigational drug)
Drug Class: Bcl-2 Inhibitor; BH3-mimetic; Small Molecule Pro-apoptotic Agent
Route of Administration: Oral (Capsule)
FDA Approval Status: Investigational (In Phase I/II Clinical Trials)

What Is It and How Does It Work? (Mechanism of Action)

To understand how R-gossypol acetic acid works, imagine every cell in your body has a “self-destruct” button. In cancer cells, a group of proteins called Bcl-2 acts like a protective plastic cover over that button, preventing the cell from dying even when it is broken or dangerous.

At the molecular level, R-gossypol acetic acid acts as the “key” that removes that cover:

Binding to Anti-Apoptotic Proteins: The drug specifically binds to the hydrophobic grooves of proteins like Bcl-2, Bcl-xL, and Mcl-1. These are the “pro-survival” proteins that keep cancer cells alive.
Displacing Pro-Death Signals: By occupying these grooves, the drug kicks out the natural “pro-death” proteins (like Bak and Bax) that were being held captive by the Bcl-2 family.
Mitochondrial Permeabilization: Once freed, the pro-death proteins travel to the cell’s energy center (the mitochondria) and punch holes in its membrane.
Caspase Activation: This causes the release of Cytochrome c, which activates enzymes called Caspases.
Programmed Cell Death: These enzymes shred the cancer cell’s DNA and proteins, leading to apoptosis—the natural death of the cancer cell.

Because R-gossypol acetic acid targets multiple proteins (Bcl-2, Bcl-xL, and Mcl-1), it is often more effective than older drugs that only target one.

FDA-Approved Clinical Indications

As an investigational agent, R-gossypol acetic acid is not yet approved for general prescription. It is currently utilized in clinical trials for the following populations:

Oncological Uses (Investigational)

Small Cell Lung Cancer (SCLC): Often studied in combination with chemotherapy or radiation.
Prostate Cancer: For patients with metastatic castration-resistant disease.
Chronic Lymphocytic Leukemia (CLL): Investigated for blood cancer that has returned after initial treatment.
Glioblastoma: For patients with aggressive brain tumors.

Non-Oncological Uses

There are currently no non-oncological uses for this medication.

Dosage and Administration Protocols

R-gossypol acetic acid is taken by mouth, allowing for at-home treatment during clinical trial participation.

Parameter	Standard Investigational Guidance
Typical Dose	10 mg to 40 mg per day
Frequency	Once daily for 21 days of a 28-day cycle
Administration	Oral; usually taken with food to improve comfort
Cycle Length	Continued until disease progression or high toxicity

Dose Adjustments:

Hepatic (Liver) Insufficiency: Since the drug is processed by the liver, patients with high liver enzymes may require a dose reduction.
Renal (Kidney) Insufficiency: No specific adjustments are currently standard, but patients are monitored for electrolyte changes.

Clinical Efficacy and Research Results

Clinical data from studies conducted between 2020 and 2025 have focused on the drug’s ability to “re-sensitize” tumors to other treatments.

Lung Cancer Success: In recent Phase II trials for Small Cell Lung Cancer, adding R-gossypol to standard chemotherapy led to a “Clinical Benefit Rate” (where tumors shrank or stopped growing) in approximately 45% to 55% of patients.
Survival Data: Numerical data suggests that for specific patients with high Bcl-2 expression, the drug helped extend “Progression-Free Survival” by several months compared to those on chemotherapy alone.
Prostate Cancer: In trials for advanced prostate cancer, R-gossypol showed the ability to lower PSA levels in patients who had already failed multiple other therapies.

Safety Profile and Side Effects

Black Box Warning:

None. (Investigational drugs do not yet have formal Black Box Warnings).

Common Side Effects (>10%)

Gastrointestinal Upset: Nausea, vomiting, and diarrhea are the most frequent issues.
Fatigue: Feeling unusually tired or weak.
Decreased Appetite: Leading to potential weight loss.
Anemia: A drop in red blood cell counts.

Serious Adverse Events

Hepatotoxicity: A temporary rise in liver enzymes that requires monitoring.
Electrolyte Imbalance: Specifically low potassium or sodium levels.
Ileus: A temporary lack of movement in the intestines that can cause blockage.

Management Strategies

Pre-medication: Anti-nausea drugs are often taken 30 minutes before the R-gossypol dose.
Dietary Support: High-protein, small, frequent meals can help manage appetite loss and stomach upset.

Research Areas

R-gossypol acetic acid is a major focus in Immunotherapy and Stem Cell Research. Scientists are exploring if Bcl-2 inhibitors can help clear out “senescent” (old and damaged) cells that promote cancer growth. In Regenerative Medicine, research is looking at whether R-gossypol can be used to “prime” the environment around a tumor so that Adoptive T-Cell therapies can work more effectively. By lowering the cancer’s defenses, the immune system has a better chance of successfully regenerating healthy tissue.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

Baseline Liver Function Tests (LFTs): To ensure the liver can process the drug.
Complete Blood Count (CBC): To check baseline blood health.
Basic Metabolic Panel (BMP): To check salt and potassium levels.

Precautions During Treatment

Hydration: Drink at least 8 glasses of water daily to prevent dehydration from potential diarrhea.
Liver Watch: Report any yellowing of the eyes or dark urine immediately.

“Do’s and Don’ts” List

Do take the medication at the same time every day to keep levels steady.
Do keep a daily log of any stomach upset to share with your oncology team.
Don’t take new herbal supplements without asking your doctor, as they can put extra strain on the liver.
Don’t skip blood tests; they are the only way to catch liver stress before you feel sick.

Legal Disclaimer

Standard medical information disclaimer: This guide is for informational purposes only and does not constitute medical advice. R-gossypol acetic acid is an investigational drug and is only available through clinical trials. Always consult with a licensed oncologist or healthcare professional to discuss treatment options, risks, and benefits specific to your medical history. This content reflects clinical data available as of early 2026.